Citadel Advisors
SXTC icon

Citadel Advisors’s China SXT Pharmaceuticals SXTC Stock Holding History

Citadel Advisors’s Portfolio SXTC Stock Details SXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13
Closed -$241K – 14193
2025
Q4 		$241K Buy
13
+9
+225% +$156K ﹤0.01% 10635
2025
Q3 		$77.5K Buy
+4
New +$79K ﹤0.01% 11993
2024
Q3 		– Hold
0
– -$17.4K – 15221
2024
Q2 		– Hold
0
– – – 12753
2023
Q4 		– Hold
0
– -$23.5K – 15233
2023
Q3 		– Hold
0
– – – 12491
2023
Q2 		– Hold
0
– -$7.02K – 15220
2023
Q1 		– Hold
0
– – – 13762
2022
Q2 		– Hold
0
– -$75K – 14070
2022
Q1 		– Hold
0
– – – 12526
2021
Q4 		– Hold
0
– -$11K – 14730
2021
Q3 		– Hold
0
– – – 13681
2021
Q2 		– Hold
0
– – – 13352
2021
Q1 		– Hold
0
– – – 12485
2020
Q3 		– Hold
0
– -$7K – 10710
2020
Q2 		– Hold
0
– – – 9661
2020
Q1 		– Hold
0
– – – 9371

Other funds holding SXTC

SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Citadel Advisors's SXTC Position: Q1 2026 in Review

Citadel Advisors sold out of China SXT Pharmaceuticals (SXTC) in Q1 2026, closing a stake of 13 shares — an estimated $241K sold.

Citadel Advisors first reported a position in SXTC in Q3 2025 and held it in 2 quarters. The position peaked at $241K in Q4 2025. 1 fund tracked by Wall St. Rank holds SXTC as of Q1 2026.

  • Citadel Advisors reported no remaining China SXT Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 13 China SXT Pharmaceuticals shares in Q1 2026, an estimated $241K.
  • Citadel Advisors first reported a position in China SXT Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Citadel Advisors's China SXT Pharmaceuticals position peaked at $241K in Q4 2025.
  • 1 fund tracked by Wall St. Rank held China SXT Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.